[Acanthamoeba keratitis: about the first two Tunisian cases].
Acanthamoeba keratitis is a rare but severe corneal infection which, despite improvements in diagnosis and treatment, still culminates in prolonged morbidity and significant loss of visual acuity. We present the case report of the first identification of Acanthamoeba as a causative agent of keratitis in Tunisia. Case no 1: A 20-year-old girl, nearsighted corrected with soft contact lenses, suffering from a deep corneal inflammation and poor visual acuity The ophthalmological examination showed bilateral dendritiform epithelial keratitis. The illness did not respond to topical and general antibiotic treatment and developed bilateral corneal abscess. Microscopic examination and culture of samples from cornea scraping revealed the presence of trophozoit and cysts of Acanthamoeba associated with Fusarium oxysporum. As the treatment with local Ketoconazol and antibiotherapy didn't show any result, two transfixiant keratoplasty were carried out and treatment by Désomédine, PHMB (polyhexamethylene biguanide) and Voriconazol was started. After two months, the patient felt better, vision was also improved (2/10) and infiltrates became smaller Case no 2: A 19-year-old girl, nearsighted with soft contact lenses consulted for a bilateral corneal ulceration and poor vision (1/20). Trophozoit and cysts of Acanthamoeba were found in the contact lens solution. She was treated quickly with Désomédine. Visual acuity improved to 7/10 but the corneal ulceration left a residual opacity
Ben Salah
S
S
Service d'ophtalmologie, CHU Habib-Bourguiba, Sfax, Tunisie.
Makni
F
F
Cheikrouhou
F
F
Ben Zina
Z
Z
Mlik
M
M
Feki
J
J
Colin
J
J
Ayadi
A
A
D000048:Acanthamoeba / Q000302:isolation & purification*; D015823:Acanthamoeba Keratitis / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology* / Q000601:surgery; D000328:Adult; D000563:Amebicides / Q000600:supply & distribution; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D001550:Benzamidines / Q000627:therapeutic use; D001645:Biguanides / Q000627:therapeutic use; D003263:Contact Lenses, Hydrophilic; D004359:Drug Therapy, Combination; D015821:Eye Infections, Fungal / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology* / Q000601:surgery; D005260:Female; D005670:Fusarium / Q000302:isolation & purification*; D006801:Humans; D015948:Keratoplasty, Penetrating; D007654:Ketoconazole / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014416:Tunisia / Q000453:epidemiology; D065819:Voriconazole
D000563:Amebicides; D000935:Antifungal Agents; D001550:Benzamidines; D001645:Biguanides; D011743:Pyrimidines; D014230:Triazoles; C031233:polihexanide; C018961:hexamidine; D065819:Voriconazole; D007654:Ketoconazole